Company* | Company* | Product | Terms/Details (Date) |
| | |||
Celltech Group | Biochemie | PEGylated antibody fragment-based drugs | Biochemie will manufacture and supply the drugs to Celltech with a fixed annual manufacturing capacity from 2004 to 2010 (9/12) |
GeneMachines | Carsen Group | OmniGrid and OmniGrid Accent microarrayers | Exclusive distribution agreement; financial terms were not disclosed (8/29) |
Insmed | Avecia Biotechnology Inc.* (UK) | SomatoKine, and its component proteins, insulin-like growth factor-1 and insulin-like growth factor binding protein-3 | Avecia will manufacture the drug candidate and its component proteins (7/29) |
InterMune Inc. | Accredo Health Inc. (ACDO) | Actimmune | Accredo will distribute Actimmune; financial terms were not disclosed (8/26) |
Keryx | PolyPeptide | KRX-123 | Agreement for the scaled-up production of KRX-123, a peptide drug candidate for the treatment of hormone-refractory prostate cancer (8/22) |
Meditech | SkyePharma | Solarase | Reciprocal licensing agreement in which SkyePharma reacquires the territorial rights in certain Pacific Rim territories in return for an up-front payment, a milestone on eventual product registration in Australia or New Zealand, and a royalty on sales; SkyePharma gains the exclusive right to manufacture and market or sublicense Solarase in Australia, New Zealand, Singapore and Malaysia, while Meditech obtains equivalent rights in China, Taiwan, Indonesia and the Philip- pines (9/9) |
Ribozyme Pharmaceuticals Inc. (RZYM) | Prime | Ribozyme's new generation of controlled pore glass solid support technology | Prime Synthesis will market Ribozyme's technology exclusively (8/22) |
| | |||
Notes: | |||
# The information in the chart does not cover agricultural agreements. | |||
* Private companies are indicated with an asterisk. | |||
Unless otherwise noted, stock symbols listed are on the Nasdaq market. | |||
ASX = Australian Stock Exchange; LSE = London Stock Exchange; SWX = Swiss Stock Exchange | |||
